Prothena Corp. (PRTA) Misses Q1 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/11/2026
- Wall Street ends down as US-Iran peace optimism fades
- S&P 500 EPS growth above 20% is rare. Why 2027 may be at risk
- Goldman Sachs warns AI investment may be crowding out other business spending
- Why Wednesday's inflation print could provide the next dovish catalyst
- Tesla needs Robotaxi flywheel proof to boost investor conviction: Morgan Stanley
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
Prothena Reports Second Quarter 2015 Financial Results and Provides R&D Update
August 4, 2015 4:05 PM EDTNet cash used in operating activities was $11.1 million in the second quarter and $25.9 million for first six months of 2015; completion of successful public equity offering netting $131.4 million strengthened quarter-end cash position of $402.4 million providing solid runway for continued advancement of multiple programs Drs. Morie A. Gertz (Mayo Clinic) and Michaela Liedtke (Stanford University School of Medicine) presented updated clinical data of NEOD001 in patients with AL amyloidosis in oral sessions at ASCO and EHA, respectively, demonstrating best cardiac response rate of 57% and best renal response rate of 60% Presented... More
